The agreement calls for Stryker to market and commercialize Bio4 worldwide, with Osiris responsible for manufacturing and ongoing product research.
News of the deal comes just a few weeks after the regenerative medicine company hired Stryker’s global medical director, Dr. Jon Hopper, to be its new chief medical officer.
Bio4 is a viable bone-matrix product consisting of cells and growth factors, intended as an alternative to bone autografts harvested from the patient’s body, according to a press release. Bio4 was originally marketed under the OvationOS brand.
“Osiris was the pioneer in the allograft bone graft market with the introduction of Osteocel in 2005,” Osiris CEO Lode Debrabandere said in prepared remarks. “This partnership combines the strengths of Stryker, an industry leader in marketing orthopaedic and spine products and of Osiris, the cellular regenerative medicine leader who developed this next generation viable bone matrix.”